San Diego biopharmaceutical company Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), announced Tuesday the election of Dr. Stephen R. Biggar to its board of directors.
He will fill a vacancy on Acadia’s board and serve as a Class II director, the company said in a release, and his term will expire at the annual meeting of stockholders in 2015.
Referring to what were reported as successful results in Acadia's recent Parkinson’s disease psychosis trial using the company's drug pimavanserin, Biggar said in the release that he shares in Acadia’s enthusiasm and belief that the drug has the potential to transform the treatment landscape for Parkinson's patients.
"Following the recent financing, which raised $86 million, Acadia has a solid foundation for building the full potential of pimavanserin," Biggar said. "I look forward to being a part of the Acadia team as we work to develop and commercialize pimavanserin and other potential new drugs that may improve the lives of patients.”
Biggar is a partner at Baker Brothers Investments, a fund management company focused on long-term investments in life sciences companies. From April 2002 to October 2006, he served as a principal with the fund.
He also serves as a director for Synageva BioPharma Corp. (Nasdaq: GEVA), a publicly traded biotechnology company.
Biggar received a master's degree and a Ph.D. in immunology from Stanford University, and received a bachelor's degree in genetics from the University of Rochester.